The announcement matters because TB remains one of the leading infectious killers in South Africa, and no new vaccine against the disease has advanced this far in more than a century. If the trial succeeds, it would be the first significant improvement on a shot most South Africans received as infants and that offers little protection in adulthood.

The vaccine, known as M72, is currently in phase three trials across five countries, including South Africa, according to national Department of Health spokesperson Foster Mohale. Phase one and phase two trials showed the vaccine protected against active pulmonary TB disease, Mohale said, with minimal safety concerns recorded during those earlier stages.

"This is arguably a major step toward a new TB vaccine, the first significant advance since BCG more than 100 years ago," Mohale said. The BCG vaccine, the bacille Calmette-Guérin shot, is given to newborns and children under five. Its protection fades by adulthood, which is when TB most commonly becomes active and spreads.

Mohale said the department has plans and preparations already underway to enable an expedited rollout once M72 clears the remaining regulatory steps. Those steps are not small. The vaccine still needs full trial results and registration by the South African Health Products Regulatory Authority (SAHPRA) before any public distribution can begin.

"The Department of Health welcomes this important agreement and stands ready to support the production and introduction of the M72/AS01E vaccine in South Africa once the trial results are known and the vaccine has been registered by SAHPRA," Mohale said.

That sentence carries the real weight of the announcement. The department is not confirming a vaccine. It is confirming a posture, a readiness to act once two conditions outside its control are met: completed phase three data, and SAHPRA's sign-off.

Why BCG Fell Short

The gap this vaccine would fill is old and well documented. BCG has been in use for over a century. It works reasonably well in infants, cutting the risk of severe forms of TB in early childhood. But its protective effect diminishes over time. By the time most people reach the age when TB is most likely to progress from latent infection to active, contagious disease, BCG offers little defense.

Related News

That gap has left a treatment and prevention landscape unchanged for generations, even as TB has remained a leading cause of death from an infectious disease in South Africa. M72 is designed to work differently. It targets adolescents and adults, the population BCG effectively stops protecting. The full name of the shot, M72/AS01E, reflects a combination of an antigen and an adjuvant, the latter developed to boost immune response in older populations.

What Phase Three Will Have to Prove

Phase one and two trials, according to Mohale, showed protection against active pulmonary TB disease specifically, the form of TB that spreads through the air and drives most transmission. Mohale described the safety profile from those trials as showing minimal concerns, though he did not cite specific adverse event data, and none was provided in the department's statement.

Phase three is the larger test. It is running concurrently in five countries, one of them South Africa, a detail Mohale confirmed but did not expand on with site locations or enrollment numbers. Phase three trials typically involve larger and more diverse populations than earlier phases, designed to catch rarer side effects and confirm efficacy across different groups before regulators will consider approval.

No date has been given for when phase three results are expected. No number has been attached to how many South African participants are enrolled, and the department's statement did not name the trial sites or the research partners running the South African leg of the study.

The Regulatory Bottleneck

SAHPRA has not issued its own public statement on M72, based on the information provided by the Department of Health. Registration through SAHPRA is a legally required step before any vaccine can be distributed in South Africa, regardless of trial outcomes elsewhere. The department's comments describe readiness to support "production and introduction" once that registration happens, but they do not detail what that support would look like in practice, whether financial, logistical, or regulatory.

Mohale's framing, that the department "stands ready," is a statement of intent, not a commitment backed by a published implementation plan. No timeline, budget, or distribution strategy accompanied the announcement.

The 2030 elimination target Mohale referenced aligns with global TB reduction goals that predate this specific vaccine trial. Whether M72 alone could meaningfully move South Africa toward that target, given the scale of the country's existing TB burden, was not addressed in the department's statement.

What happens next depends on data the department itself does not yet have. Phase three results have not been published. SAHPRA has not registered the vaccine. Until both happen, the department's readiness remains a plan on paper, not a vaccine in arms.